{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:08:47Z","timestamp":1788484127888,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2013,2,27]],"date-time":"2013-02-27T00:00:00Z","timestamp":1361923200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s00228-013-1483-y","type":"journal-article","created":{"date-parts":[[2013,2,26]],"date-time":"2013-02-26T04:48:01Z","timestamp":1361854081000},"page":"1467-1475","source":"Crossref","is-referenced-by-count":40,"title":["A population-based study of dosing and persistence with anti-dementia medications"],"prefix":"10.1007","volume":"69","author":[{"given":"Linda","family":"Brewer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cora","family":"McGreevy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,2,27]]},"reference":[{"key":"1483_CR1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jalz.2007.04.381","volume":"3","author":"R Brookmeyer","year":"2007","unstructured":"Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM (2007) Forecasting the global burden of Alzheimer\u2019s disease. Alzheimer\u2019s Dementia 3:186\u2013191","journal-title":"Alzheimer\u2019s Dementia"},{"key":"1483_CR2","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1176\/appi.ajp.157.5.708","volume":"157","author":"CG Lyketsos","year":"2000","unstructured":"Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC (2000) Mental and behavioral disturbances in dementia: findings from the Cache County study on memory in aging. Am J Psychiatry 157:708\u2013714","journal-title":"Am J Psychiatry"},{"issue":"4","key":"1483_CR3","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/ageing\/afl027","volume":"35","author":"N Tabet","year":"2006","unstructured":"Tabet N (2006) Acetylcholinesterase inhibitors for Alzheimer\u2019s disease: anti-inflammatories in acetylcholine clothing! Age Ageing 35(4):336\u2013338","journal-title":"Age Ageing"},{"key":"1483_CR4","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/S0149-2918(04)90172-5","volume":"26","author":"SI Finkel","year":"2004","unstructured":"Finkel SI (2004) Effects of rivastigmine on behavioural and psychological symptoms of dementia in Alzheimer\u2019s disease. Clin Ther 26:980\u2013990","journal-title":"Clin Ther"},{"key":"1483_CR5","doi-asserted-by":"crossref","unstructured":"Birks J (2006) Cholinesterase inhibitors for Alzheimer\u2019s Disease. Cochrane Database Syst Rev 2006 (1):CD005593","DOI":"10.1002\/14651858.CD005593"},{"key":"1483_CR6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/gps.1402","volume":"21","author":"A Takeda","year":"2006","unstructured":"Takeda A, Loveman E, Clegg A et al (2006) A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer\u2019s disease. Int J Geriatr Psychiatry 21:17\u201328","journal-title":"Int J Geriatr Psychiatry"},{"key":"1483_CR7","doi-asserted-by":"crossref","unstructured":"McShane R, Areosa SA, Minakaran N (2006) Memantine for dementia. Cochrane Database Syst Rev 2006 (2):CD003154","DOI":"10.1002\/14651858.CD003154.pub5"},{"key":"1483_CR8","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2165\/00002512-200825070-00004","volume":"25","author":"GT Grossberg","year":"2008","unstructured":"Grossberg GT (2008) Impact of rivastigmine on caregiver burden associated with Alzheimer\u2019s disease in both informal care and nursing home settings. Drugs Aging 25:573\u2013584","journal-title":"Drugs Aging"},{"key":"1483_CR9","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/archneur.58.3.427","volume":"58","author":"RS Doody","year":"2001","unstructured":"Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD (2001) Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 58:427\u2013433","journal-title":"Arch Neurol"},{"key":"1483_CR10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1001\/archneur.61.2.252","volume":"61","author":"MA Raskind","year":"2004","unstructured":"Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CV (2004) The cognitive benefits of galantamine are sustained for at least 36\u00a0months: a long-term extension trial. Arch Neurol 61:252\u2013256","journal-title":"Arch Neurol"},{"key":"1483_CR11","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000008243","volume":"44","author":"M Farlow","year":"2000","unstructured":"Farlow M, Anand R, Messina J, Hartman R, Veach J (2000) A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer\u2019s disease. Eur Neurol 44:236\u2013241","journal-title":"Eur Neurol"},{"key":"1483_CR12","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1106668","volume":"366","author":"R Howard","year":"2012","unstructured":"Howard R, McShane R, Lindesay J et al (2012) Donepezil and memantine for Moderate-to-Severe Alzheimer\u2019s disease. N Engl J Med 366:893\u2013903","journal-title":"N Engl J Med"},{"key":"1483_CR13","unstructured":"electronic Medicines Compendium (eMC). Available at: http:\/\/www.medicines.org.uk\/emc\/"},{"issue":"17","key":"1483_CR14","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJM199504273321703","volume":"332","author":"SE Andrade","year":"1995","unstructured":"Andrade SE, Walker AM, Gottlieb LK et al (1995) Discontinuation of antihyperlipidemic drugs: do rates reported in clinical trials reflect rates in primary care setting? N Engl J Med 332(17):1125\u20131131","journal-title":"N Engl J Med"},{"key":"1483_CR15","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2165\/00002512-200522080-00006","volume":"22","author":"DC Suh","year":"2005","unstructured":"Suh DC, Thomas SK, Valiyeva E, Arcona S, Vo L (2005) Drug persistency of two cholinesterase inhibitors:rivastigmine versus donepezil in elderly patients with Alzheimer\u2019s disease. Drugs Aging 22:695\u2013707","journal-title":"Drugs Aging"},{"key":"1483_CR16","doi-asserted-by":"crossref","first-page":"451","DOI":"10.18553\/jmcp.2008.14.5.451","volume":"14","author":"L Mucha","year":"2008","unstructured":"Mucha L, Shaohung S, Cuffel B, McRae T, Mark TL, Del Valle M (2008) Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer\u2019s disease. J Manag Care Pharm 14:451\u2013461","journal-title":"J Manag Care Pharm"},{"issue":"12","key":"1483_CR17","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/gps.3778","volume":"27","author":"T Thiruchselvam","year":"2012","unstructured":"Thiruchselvam T, Naglie G, Moineddin R et al (2012) Risk factors for medication nonadherence in older adults with cognitive impairment who live alone. Int J Geriatr Psychiatry 27(12):1275\u20131282","journal-title":"Int J Geriatr Psychiatry"},{"key":"1483_CR18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.18553\/jmcp.2005.11.3.231","volume":"11","author":"JA Mauskopf","year":"2005","unstructured":"Mauskopf JA, Paramore C, Lee WC, Snyder EH (2005) Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. J Mang Care Pharm 11:231\u2013251","journal-title":"J Mang Care Pharm"},{"key":"1483_CR19","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/cncr.22485","volume":"109","author":"TI Barron","year":"2007","unstructured":"Barron TI, Connolly RM, Bennett K, Feely J, Kennedy MJ (2007) Early discontinuation of tamoxifen. A lesson for oncologists. Cancer 109:832\u2013839","journal-title":"Cancer"},{"key":"1483_CR20","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00228-005-0980-z","volume":"61","author":"S Perreault","year":"2005","unstructured":"Perreault S, Blais L, Dragomir A et al (2005) Persistence and determinants of statin therapy among middle-ages patients free of cardiovascular disease. Eur J Clin Pharmacol 61:667\u2013674","journal-title":"Eur J Clin Pharmacol"},{"key":"1483_CR21","unstructured":"Irish Health Services Executive (HSE) Primary Care Reimbursement Services (PCRS) pharmacy-claims database. Available at: http:\/\/www.hse.ie\/eng\/Staff\/PCRS\/"},{"key":"1483_CR22","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/WNL.50.1.136","volume":"50","author":"SL Rogers","year":"1998","unstructured":"Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT (1998) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer\u2019s disease. Donepezil study group. Neurology 50:136\u2013145","journal-title":"Neurology"},{"key":"1483_CR23","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.318.7184.633","volume":"318","author":"M R\u00f6sler","year":"1999","unstructured":"R\u00f6sler M, Anand R, Cicin-Sain A et al (1999) Efficacy and safety of rivastigmine in patients with Alzheimer\u2019s disease: international randomised controlled trial. BMJ 318:633\u2013638","journal-title":"BMJ"},{"key":"1483_CR24","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","volume":"54","author":"MA Raskind","year":"2000","unstructured":"Raskind MA, Peskind ER, Wessel T, Yuan W (2000) Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The galantamine USA-1 study group. Neurology 54:2261\u20132268","journal-title":"Neurology"},{"key":"1483_CR25","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jama.291.3.317","volume":"291","author":"PN Tariot","year":"2004","unstructured":"Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, Memantine Study Group (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291:317\u2013324","journal-title":"JAMA"},{"key":"1483_CR26","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/j.1532-5415.2005.53384_9.x","volume":"53","author":"G Singh","year":"2005","unstructured":"Singh G, Thomas S, Vijayabharathi L (2005) Treatment and persistency with rivastigmine and donepezil in a large state Medicaid program. J Am Geriatr Soc 53:1269\u20131270","journal-title":"J Am Geriatr Soc"},{"key":"1483_CR27","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1532-5415.2009.02075.x","volume":"57","author":"L Blais","year":"2009","unstructured":"Blais L, Kergoat MJ (2009) Adherence to cholinesterase inhibitors in patients with alzheimers disease. J Am Geriatr Soc 57:366\u2013368","journal-title":"J Am Geriatr Soc"},{"key":"1483_CR28","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2165\/00002512-200724110-00001","volume":"24","author":"B Seltzer","year":"2007","unstructured":"Seltzer B (2007) Is long-term treatment of Alzheimer\u2019s disease with cholinesterase inhibitor therapy justified? Drugs Aging 24:881\u2013890","journal-title":"Drugs Aging"},{"key":"1483_CR29","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S0149-2918(98)80139-2","volume":"20","author":"R Balkrishnan","year":"1998","unstructured":"Balkrishnan R (1998) Predictors of medication adherence in the elderly. Clin Ther 20:764\u2013771","journal-title":"Clin Ther"},{"key":"1483_CR30","doi-asserted-by":"crossref","unstructured":"Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X (2008) Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008 (2):CD000011","DOI":"10.1002\/14651858.CD000011.pub3"},{"key":"1483_CR31","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Oterberg","year":"2005","unstructured":"Oterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487\u2013497","journal-title":"N Engl J Med"},{"key":"1483_CR32","unstructured":"National Institute for Health and Clinical Excellence (NICE) (2006) Dementia: Supporting people with dementia and their carers in health and social care. Clinical guidelines CG42. NICE, London"},{"key":"1483_CR33","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/jnnp.2008.158964","volume":"80","author":"OL Lopez","year":"2009","unstructured":"Lopez OL, Becker JT, Wahed AS et al (2009) Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 80:600\u2013607","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"1483_CR34","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1001\/archneurol.2010.190","volume":"67","author":"CD Bushnell","year":"2010","unstructured":"Bushnell CD, Zimmer LO, Pan W, Adherence Evaluation After Ischemic Stroke\u2013Longitudinal Investigators et al (2010) Persistence with stroke prevention medications 3 months after hospitalization. Arch Neurol 67(12):1456\u20131463","journal-title":"Arch Neurol"},{"key":"1483_CR35","unstructured":"Alzheimer\u2019s Research Trust (2010): Dementia 2010 Report. Alzheimer\u2019s Research Trust UK, Cambridge"},{"key":"1483_CR36","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1212\/WNL.0b013e318216eb7b","volume":"76","author":"MS Rafii","year":"2011","unstructured":"Rafii MS, Walsh S, Little JT et al (2011) Alzheimer\u2019s Disease Cooperative Study. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology 76:1389\u20131394","journal-title":"Neurology"},{"key":"1483_CR37","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archneurol.2011.233","volume":"69","author":"S Craft","year":"2012","unstructured":"Craft S, Baker LD, Montine TJ (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 69:29\u201338","journal-title":"Arch Neurol"},{"key":"1483_CR38","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1212\/WNL.0b013e3182553be6","volume":"78","author":"EMC Schrijvers","year":"2012","unstructured":"Schrijvers EMC, Verhaaren BFJ, Koudstaal PJ et al (2012) Is dementia incidence declining? Trends in dementia incidence since 1990 in the Rotterdam study. Neurology 78:1456\u20131463","journal-title":"Neurology"},{"issue":"17","key":"1483_CR39","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/WNL.0b013e318217e7a4","volume":"76","author":"J Li","year":"2011","unstructured":"Li J, Wang YJ, Zhang M, Chongqing Ageing Study Group et al (2011) Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology 76(17):1485\u20131491","journal-title":"Neurology"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-013-1483-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-013-1483-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-013-1483-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T13:21:33Z","timestamp":1644412893000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-013-1483-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,27]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["1483"],"URL":"https:\/\/doi.org\/10.1007\/s00228-013-1483-y","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,27]]}}}